



04-08-04

Express Mail No. EV335859416US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Oshlack et al. Confirmation No.: 4265  
Serial No.: 10/731,678 Art Unit: 1432  
Filed: December 8, 2003 Examiner: To Be Assigned  
For: ORALLY ADMINISTABLE Attorney Docket No.: 6750-264-999  
OPIOID FORMULATIONS (CAM: 305158-999262)  
HAVING EXTENDED  
DURATION OF EFFECT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
  - 1a. A list of all patents, publications, applications, or other information submitted for consideration by the office on Revised Form PTO-1449 (References A01-A101; B01-B54; and C01-C37).
  - 1b. A legible copy of References B50-B54.
2. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of a first Office action on the merits.
3. This application is a continuation application under 37 C.F.R. §1.53(b) or (d).
  - 3a. Copies of References **A01-A101**; **B01-B49** and **C01-C37** listed on Revised Form PTO-1449 were previously cited and submitted in prior Application Nos. 10/392,586, filed March 20, 2003; 09/891,882, filed June 26, 2001, now U.S. Patent No. 6,572,885; 09/390,719, filed September 7, 1999 now U.S. Patent No. 6,294,195; 08/508,246, filed July 27, 1995, now U.S. Patent No. 5,968,551; 08/133,503, filed October 7, 1993, abandoned; 08/081,618 filed June 23, 1993, now U.S. Patent No. 5,472,712; 08/086,248 filed July 1, 1993, abandoned; 07/814,111, filed December, 24, 1991, now U.S. Patent No. 5,273,760; 08/097,558, filed July 27, 1993, now U.S. Patent No. 5,580,578; 07/826,084 filed January 27, 1992, now U.S. Patent No. 5,286,493, all to which this application claims priority under 35 U.S.C. §120, and are not being submitted pursuant to 37 C.F.R. §1.98(d).
  - 3b. Copies of References **B50-B54** listed on Form PTO-1449 were not previously cited in the prior applications, and are provided herewith.

4. The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Jones Day Deposit Account No. 503013.
5. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Date: April 6, 2004

Respectfully submitted,


*Gidon D. Stern* Reg. No.: 27,469  
*by Brian C. Romy* Reg. No.: 48,176 27,469

Gidon D. Stern (Reg. No.)  
JONES DAY  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939

Enclosures

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY DOCKET NO.

6750-264-999

(CAM: 305158-999262)

APPLICATION NO

10/731,678

APPLICANT

Oshlack et al.

FILING DATE

December 8, 2003

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	3,567,650	3/1971	Bakan	252	316	
	A02	3,634,584	1/1972	Poole	424	21	
	A03	3,845,770	11/1974	Theeuwes et al.	128	260	
	A04	3,870,790	3/1975	Lowey et al.	424	19	
	A05	3,901,968	8/1975	Cohen et al.	424	22	
	A06	3,901,969	8/1975	Cohen et al.	424	22	
	A07	3,916,899	11/1975	Theeuwes et al.	128	145.8	
	A08	3,935,326	1/1976	Groppenbacher et al.	427	3	
	A09	4,060,598	11/1977	Groppenbacher et al.	424	33	
	A10	4,088,798	5/1978	Michaelis	427	3	
	A11	4,138,475	2/1979	McAinsh et al.	424	19	
	A12	4,377,568	3/1983	Chopra	424	31	
	A13	4,385,078	5/1983	Onda et al.	427	3	
	A14	4,389,393	6/1983	Schor et al.	424	19	
	A15	4,443,497	4/1984	Samejima et al.	427	213.36	
	A16	4,483,847	11/1984	Augart	424	22	
	A17	4,520,172	5/1985	Lehmann et al.	525	369	
	A18	4,548,990	10/1985	Mueller et al.	525	123	
	A19	4,557,925	12/1985	Lindahl et al.	424	19	
	A20	4,600,645	7/1986	Ghebre-Sellassie et al.	428	403	
	A21	4,705,695	11/1987	Lehmann et al.	427	3	
	A22	4,708,874	11/1987	De Haan et al.	424	470	
	A23	4,728,513	3/1988	Ventouras	424	461	
	A24	4,756,911	7/1988	Drost et al.	424	468	
	A25	4,766,012	8/1988	Valenti	427	213.36	
	A26	4,784,858	11/1988	Ventouras	424	468	
	A27	4,786,505	11/1988	Lovgren et al.	424	468	
	A28	4,786,506	11/1988	Fontanelli	424	470	
	A29	4,795,327	1/1989	Gaylord et al.	424	468	
	A30	4,797,410	1/1989	El-Fakahany	514	356	
	A31	4,798,724	1/1989	Khanna	424	480	
	A32	4,806,337	2/1989	Snipes et al.	71	65	
	A33	4,810,501	3/1989	Ghebre-Sellassie et al.	424	469	
	A34	4,828,836	5/1989	Elger et al.	424	419	
	A35	4,834,984	5/1989	Goldie et al.	424	488	

	A36	4,834,985	5/1989	Elger et al.	424	488	
	A37	4,837,004	6/1989	Wu et al.	424	438	
	A38	4,837,033	6/1989	Kokubo et al.	424	494	
	A39	4,844,907	7/1989	Elger et al.	424	465	
	A40	4,844,909	7/1989	Goldie et al.	424	480	
	A41	4,849,229	7/1989	Gaylord et al.	424	468	
	A42	4,853,230	8/1989	Lovgren et al.	424	466	
	A43	4,861,598	8/1989	Oshlack	424	468	
	A44	4,891,230	1/1990	Geoghegan et al.	424	461	
	A45	4,954,350	9/1990	Jones et al.	424	493	
	A46	4,970,075	11/1990	Oshlack	424	451	
	A47	4,983,730	1/1991	Domeshek et al.	536	69	
	A48	4,990,341	2/1991	Goldie et al.	424	484	
	A49	5,007,790	4/1991	Shell	424	451	
	A50	5,008,118	4/1991	Iwanami et al.	424	498	
	A51	5,009,897	4/1991	Brinker et al.	424	469	
	A52	5,019,397	5/1991	Wong et al.	424	473	
	A53	5,024,842	6/1991	Edgren et al.	424	473	
	A54	5,047,258	9/1991	Belanger et al.	427	3	
	A55	5,064,650	11/1991	Lew	424	435	
	A56	5,068,110	11/1991	Fawzi et al.	424	461	
	A57	5,071,646	12/1991	Malkowska et al.	424	497	
	A58	5,077,053	12/1991	Kuncewitch et al.	424	441	
	A59	5,084,278	1/1992	Mehta	424	441	
	A60	5,085,866	2/1992	Cowsar et al.	424	481	
	A61	5,091,175	2/1992	Imondi et al.	424	486	
	A62	5,096,717	3/1992	Wirth et al.	424	490	
	A63	5,112,384	5/1992	Miura et al.	71	92	
	A64	5,112,621	5/1992	Stevens et al.	424	497	
	A65	5,122,384	6/1992	Paradissis et al.	424	451	
	A66	5,130,171	7/1992	Prud'Homme et al.	427	213.36	
	A67	5,133,974	7/1992	Paradissis et al.	424	480	
	A68	5,158,777	10/1992	Abramowitz et al.	424	458	
	A69	5,160,742	11/1992	Mazer et al.	424	469	
	A70	5,169,645	12/1992	Shukla et al.	424	499	
	A71	5,171,580	12/1992	Iamartino et al.	424	490	
	A72	5,178,866	1/1993	Wright et al.	424	473	
	A73	5,178,868	1/1993	Malnmqvist-Granlund et al.	424	490	
	A74	5,186,937	2/1993	Sparks et al.	424	438	
	A75	5,202,128	4/1993	Morella et al.	424	469	
	A76	5,202,159	4/1993	Chen et al.	427	213.31	
	A77	5,213,811	5/1983	Frisbee et al.	424	493	
	A78	5,219,621	6/1993	Geoghegan et al.	424	462	
	A79	5,266,331	11/1993	Oshlack et al.	424	468	
	A80	5,273,760	12/1993	Oshlack et al.	424	480	

	A81	5,283,065	2/1994	Doyon et al.	424	467	
	A82	5,286,493	2/1994	Oshlack et al.	424	468	
	A83	5,288,505	2/1994	Deboeck et al.	424	497	
	A84	5,321,012	6/1994	Mayer et al.	514	25	
	A85	5,330,766	7/1994	Morella et al.	424	490	
	A86	5,378,474	1/1995	Morella et al.	424	469	
	A87	5,411,745	5/1995	Oshlack et al.	424	456	
	A88	5,456,923	10/1995	Nakamichi et al.	424	489	
	A89	5,460,826	10/1995	Merrill et al.	424	470	
	A90	5,472,712	12/1995	Oshlack et al.	424	480	
	A91	5,500,227	3/1996	Oshlack et al.	424	476	
	A92	5,508,042	4/1996	Oshlack et al.	424	468	
	A93	5,520,931	5/1996	Persson et al.	424	473	
	A94	5,549,912	8/1996	Oshlack et al.	424	468	
	A95	5,580,578	12/1996	Oshlack et al.	424	468	
	A96	5,601,842	2/1997	Bartholomaeus	424	464	
	A97	5,614,218	3/1997	Olsson et al.	424	456	
	A98	5,672,360	9/1997	Sackler et al.	424	490	
	A99	5,968,551	10/1999	Oshlack et al.	424	456	
	A100	6,103,261	8/2000	Chasin et al.	424	459	
	A101	6,143,322	11/2000	Sackler et al.	424	459	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	0 097 523	1/1984	EP				
	B02	0 108 218	5/1984	EP				
	B03	0 147 780	7/1985	EP				
	B04	0 235 986	9/1987	EP				
	B05	0 253 104	1/1988	EP				
	B06	0 271 193	6/1988	EP				
	B07	0 327 295	8/1989	EP				
	B08	0 377 517	7/1990	EP				
	B09	0377 518	7/1990	EP				
	B10	0 388 954	9/1990	EP				
	B11	0 415 693	3/1991	EP				
	B12	0 463 877	1/1992	EP				
	B13	0 514 814	11/1992	EP				
	B14	0 532 348	3/1993	EP				
	B15	0 533 297	3/1993	EP				
	B16	0 534 628	3/1993	EP				
	B17	0 535 841	4/1993	EP				
	B18	0 546 676	6/1993	EP				
	B19	0 548 448	6/1993	EP				
	B20	0 580 860	2/1994	EP				
	B21	0 609 961	8/1994	EP				

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B22	0 636 370	2/1995	EP				
	B23	0 665 010	8/1995	EP				
	B24	WO 92/01446	2/1992	PCT				
	B25	WO 92/06679	4/1992	PCT				
	B26	WO 93/04675	3/1993	PCT				
	B27	WO 93/10765	6/1993	PCT				
	B28	WO 93/18753	9/1993	PCT				
	B29	WO 94/03160	2/1994	PCT				
	B30	WO 94/03161	2/1994	PCT				
	B31	WO 94/05262	3/1994	PCT				
	B32	WO 94/22431	10/1994	PCT				
	B33	WO 96/00066	1/1996	PCT				
	B34	WO 96/01629	1/1996	PCT				
	B35	WO 96/14058	5/1996	PCT				
	B36	AU-A- 47732/90	7/1990	Australia				
	B37	AU-B- 16326/92	11/1992	Australia				
	B38	AU-B-41654/93	2/1995	Australia				
	B39	CA 2082573	7/2002	Canada				
	B40	CA 2131350	4/1995	Canada				
	B41	JP 60-166608	8/1985	Japan				
	B42	JP 3-114	1/1991	Japan				
	B43	JP 4-312524	11/1992	Japan				
	B44	JP 4-321621	11/1992	Japan				
	B45	JP 63-30427	11/19948	Japan				
	B46	177293	1/1992	Taiwan				
	B47	GB 2053681	2/1981	United Kingdom				
	B48	GB 2170104	7/1986	United Kingdom				
	B49	GB 2178313	2/1987	United Kingdom				
	B50	WO 03/004029 A1	1/16/2003	PCT				
	B51	WO 03/004030 A1	1/16/2003	PCT				
	B52	WO 03/004031 A1	1/16/2003	PCT				
	B53	WO 03/004032 A1	1/16/2003	PCT				
	B54	WO 03/004033 A1	1/16/2003	PCT				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	A protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol® to Ms. Contin® in the Management of Patients with moderate to Severe Cancer Pain" ("the Protocol"). The date of the Protocol is indicated as Feb. 10, 1992 and it bears CDD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, an Australian company
C02	Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society (May 1987)
C03	Advertisement: MS Contin® ©1986, 1987 The Purdue Frederick Company
C04	Advertisement: Roxanol SR, ©1988 Roxane Laboratories, Inc.
C05	Beubler, "Medikamentöse Schmerztherapie: Kriterien, Möglichkeiten, Risiken," Therapiewoche Österreich, vol. 7, no. 2, pp. 90-96 (1992) (with English Summary)

C06	Bloomfield, et al., "Analgesic efficacy and potency of two oral controlled-release morphine preparations," Clin. Pharmacol. Ther., vol. 53, no. 4, pp. 469-478 (1993)
C07	Broomhead et al., "Kadian™/Kapanol™ -A Once Daily Morphine Formulation," Part A General Topics 1995; vol. 31A, Suppl. 5, European Journ. of Cancer (1995)
C08	Certain documents regarding Institutional Review Board Approval for the Faulding-sponsored study
C09	Certain Patient Diary Cards, Drug Disposition Records, Case Report Forms and a listing which apparently correlates patient randomization number with the treatment or dosing regimen assigned to each patient
C10	Cherry et al., "A Comparison Of Kapanol® (A New Sustained Release Morphine Formulation), MST Continus® And Morphine Solution In Cancer Patients: Morphine Metabolite Profiles And Renal Function," Abstracts 7 <sup>th</sup> World Congress on Pain, Paris, Aug. 22-27, 1993 (Abstract 999)
C11	Cherry et al., "Once a Day (i.e. 24 Hourly) Kapanol™, A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles," European Journ. of Cancer, vol. 31A, Suppl. 5, Poster 884 (1995)
C12	Dressman et al., "Storage Effects on Release from Phenylpropanolamine HCl Pellets Coated with an Ethylcellulose-based Film," 18 <sup>th</sup> Int. Symposium on Controlled Release of Bioactive Materials pp. 654-655 (1991), Amsterdam, Netherlands, pub. by the Controlled Release Society, Inc.
C13	Gourlay et al., A comparison of Kapanol® (A new sustained release morphine formulation), MST Continus® and morphine solution in cancer patients: pharmacokinetic aspects," Abstracts 7 <sup>th</sup> World Congress on Pain. Paris, Aug. 22-27, 1993 (Abstract 998)
C14	Gourlay et al., "Influence of a high-fat meal on the absorption of morphine from oral solutions," Clin. Pharmacol. Ther., Oct. pp. 463-468 (1989)
C15	Gourlay et al., "A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus®, and Morphine Solution in Cancer Patients: Pharmacokinetic Aspects of Morphine and Morphine Metabolites Progress in pain Research and Management," Proceeding of the 7 <sup>th</sup> World Congress on Pain; vol. 2, pp. 631-643 (1995)
C16	Gourlay et al., "The Reproducibility of Bio-availability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journ. of Pain and Symptom Manag., vol. 6, no. 7, pp. 431-436 (1991)
C17	Hunt et al., "Comparison of the Pharmacokinetic Profiles of Two Oral controlled-Release Morphine Formulations in Healthy Young Adults," Clin. Thera., vol. 13, no. 4, pp. 482-488 (1991)
C18	Investigator Agreements between the study organizers and certain of the principal investigators
C19	Kaiko et al., "Controlled-Release Morphine Bio-availability (MS Contin® Tablets) in the Presence and Absence of Food," The Hospice Journal, vol. 6, no. 4, pp. 17-30 (1990)
C20	Kaiko et al., "A Single-Dose Study Of The Effect Of Food Ingestion And Timing Of Dose Administration On The Pharmacokinetic Profile Of 30-MG Sustained-Release Morphine Sulfate Tablets," Current Thera. Research, vol. 47, No. 5, pp. 869-878 (1990)
C21	Kaiko, "Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient," Anesthesiol. and Pain Manag., pp. 193-212 (1991)
C22	Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Purdue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989)
C23	Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Journ. of Pain and Symptom Manag., vol. 4, no. 3, pp. 146-151 (1989)
C24	Lapin et al., "Guidelines for use of Controlled Release Oral Morphine in Cancer Pain Management," Cancer nursing, vol. 12, no. 4, pp. 202-208, 1989
C25	Maccarrone et al., "Single Dose Pharmacokinetics of Kapanol™, a New Oral Sustained-Release Morphine Formulation," Drug. Invest. vol. 7, no. 5, pp. 262-274 (1994)
C26	MS Contin—Frequency of Daily Dosing (NDTI)—Jun. 1991—May, 1992
C27	MS Contin—Frequency of Daily Dosing, Jan.-Nov. 1990
C28	Munday et al., "Changes in Drug Release Rate, Effect of Temperature and Relative Humidity on Polymeric Film Coating," 5 <sup>th</sup> Congr. Int. Tech. Pharm. vol. 2, pp. 55-60, 1989, Assoc. Pharm. Galenique Ind., Chatenay Malabry, FR
C29	Patient consent forms, apparently for four study participants
C30	Physicians Desk Reference 48 <sup>th</sup> Edition, pp. 1821-1824 (1994)
C31	Plummer et al., "A comparison of Kapanol™ (a new sustained release morphine formulation) MST Continus® and morphine solution in cancer patients: pharmacodynamic aspects" International Association for the Study of Pain, 7 <sup>th</sup> World Congress on Pain, Paris, Aug. 22-27, 1993 (Abstract 1000)
C32	Portenoy et al., "A-Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacokinetics and Pharmacodynamics of Kapanol® Capsules Given Every 24 hours and Every 12 hours with MS Contin® Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain," (1992)
C33	Slowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anaesthesia, vol. 40, pp. 438-440 (1985)
C34	Sunshine et al., "Analgesic oral efficacy of tramadol hydrochloride in postoperative pain," Clin. Pharmacol. Ther., Jun. pp. 740-746 (1992)
C35	Toner et al., "Randomized Double Blind, Phase III Crossover Study Of A New Sustained-Release Oral Morphine Formulation, Kapanol® Capsules," Abstracts 7 <sup>th</sup> World Congress on Pain, Paris, Aug. 22-27, 1993 (Abstract 1001)

	C36	West et al., "Single Dose Pharmacokinetics of a New Oral Sustained-Release Morphine Formulation, Kapanol® Capsules," Abstract 7 <sup>th</sup> World Congress on Pain, Aug. 22-27, 1993 (Abstract 997)
	C37	Yokokawa et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J, vol. 67, Suppl. 2, pp. 550-554 (1991)
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>
<b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with <b>MPEP 609</b> ; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		